疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2716人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720906, encodeId=3f3b1e20906f5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Int J Gynaecol Obstet：一项剂量范围研究，以确定每日1,2和4毫克地诺孕素对子宫内膜异位症的疗效和安全性, objectType=article, longId=168491, objectId=00a016849153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a016849153, replyNumber=0, likeNumber=65, createdTime=2019-07-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a016849153, moduleTitle=Int J Gynaecol Obstet：一项剂量范围研究，以确定每日1,2和4毫克地诺孕素对子宫内膜异位症的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a016849153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720936, encodeId=995e1e2093629, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：Daratumumab单药疗法用于淀粉样变患者的疗效和安全性, objectType=article, longId=189096, objectId=c90418909689, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c90418909689, replyNumber=0, likeNumber=86, createdTime=2020-04-14, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c90418909689, moduleTitle=Blood：Daratumumab单药疗法用于淀粉样变患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c90418909689)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720927, encodeId=32631e20927ee, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：CD19 CAT-T细胞联合依鲁替尼治疗R/R CLL的疗效和安全性, objectType=article, longId=188605, objectId=98d218860560, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98d218860560, replyNumber=0, likeNumber=101, createdTime=2020-10-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98d218860560, moduleTitle=Blood：CD19 CAT-T细胞联合依鲁替尼治疗R/R CLL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98d218860560)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720935, encodeId=59581e2093546, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, objectType=article, longId=189092, objectId=e4de1890923b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4de1890923b, replyNumber=0, likeNumber=97, createdTime=2021-01-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4de1890923b, moduleTitle=Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4de1890923b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720922, encodeId=50581e209227d, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性, objectType=article, longId=185754, objectId=cd71185e5469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd71185e5469, replyNumber=0, likeNumber=72, createdTime=2020-08-29, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd71185e5469, moduleTitle=J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd71185e5469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720916, encodeId=cca81e2091676, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=NEJM：Ubrogepant治疗偏头痛的疗效和安全性, objectType=article, longId=184215, objectId=cdd3184215d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdd3184215d1, replyNumber=0, likeNumber=86, createdTime=2020-01-31, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdd3184215d1, moduleTitle=NEJM：Ubrogepant治疗偏头痛的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdd3184215d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720910, encodeId=26931e2091074, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼, objectType=article, longId=176915, objectId=b5e21e691585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5e21e691585, replyNumber=0, likeNumber=71, createdTime=2019-11-06, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5e21e691585, moduleTitle=“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5e21e691585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720934, encodeId=4ec31e20934e9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Rheumatol：TNF抑制剂在反应性关节炎中的疗效和安全性, objectType=article, longId=189091, objectId=8a5c18909103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5c18909103, replyNumber=0, likeNumber=100, createdTime=2020-08-25, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5c18909103, moduleTitle=J Rheumatol：TNF抑制剂在反应性关节炎中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5c18909103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720904, encodeId=4a0a1e20904da, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性, objectType=article, longId=166883, objectId=967c166883ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=967c166883ab, replyNumber=0, likeNumber=59, createdTime=2019-12-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=967c166883ab, moduleTitle=Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=967c166883ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720911, encodeId=6d011e2091122, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Am J Otolaryngol：舌下尘螨滴液在单敏或者多敏过敏性鼻炎患者中的疗效和安全性评估, objectType=article, longId=177017, objectId=b8c11e701744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8c11e701744, replyNumber=0, likeNumber=72, createdTime=2020-04-26, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8c11e701744, moduleTitle=Am J Otolaryngol：舌下尘螨滴液在单敏或者多敏过敏性鼻炎患者中的疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8c11e701744)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720930, encodeId=45d51e20930b7, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：卡博替尼用于高度恶性的尤文肉瘤和骨肉瘤的疗效和安全性, objectType=article, longId=188736, objectId=b873188e361a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b873188e361a, replyNumber=0, likeNumber=75, createdTime=2020-05-08, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b873188e361a, moduleTitle=Lancet oncol：卡博替尼用于高度恶性的尤文肉瘤和骨肉瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b873188e361a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720912, encodeId=567d1e2091203, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, objectType=article, longId=178540, objectId=b7281e8540c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7281e8540c0, replyNumber=0, likeNumber=103, createdTime=2020-07-07, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7281e8540c0, moduleTitle=信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7281e8540c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720908, encodeId=c7751e2090837, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Arthritis Rheumatol：卡那奴单抗对5岁以下cryopyrin蛋白相关周期性综合征患者具有长期疗效和安全性, objectType=article, longId=174488, objectId=746a1e4488ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746a1e4488ad, replyNumber=0, likeNumber=97, createdTime=2019-11-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746a1e4488ad, moduleTitle=Arthritis Rheumatol：卡那奴单抗对5岁以下cryopyrin蛋白相关周期性综合征患者具有长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=746a1e4488ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720920, encodeId=35e61e20920c5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：IFN-K治疗系统性红斑狼疮的疗效和安全性, objectType=article, longId=185739, objectId=1d59185e39dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d59185e39dd, replyNumber=0, likeNumber=73, createdTime=2020-06-08, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d59185e39dd, moduleTitle=Ann Rheum Dis：IFN-K治疗系统性红斑狼疮的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d59185e39dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720921, encodeId=700a1e20921b2, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：NI-0101对甲氨蝶呤反应不足类风湿性关节炎患者的疗效和安全性, objectType=article, longId=185740, objectId=b523185e4089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b523185e4089, replyNumber=0, likeNumber=74, createdTime=2020-10-20, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b523185e4089, moduleTitle=Ann Rheum Dis：NI-0101对甲氨蝶呤反应不足类风湿性关节炎患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b523185e4089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720913, encodeId=3e801e209137d, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：硼替佐米、来那度胺和地塞米松诱导方案用于多发性骨髓瘤患者骨髓移植前的疗效和安全性, objectType=article, longId=179006, objectId=faa21e9006ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faa21e9006ac, replyNumber=0, likeNumber=57, createdTime=2020-08-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faa21e9006ac, moduleTitle=Blood：硼替佐米、来那度胺和地塞米松诱导方案用于多发性骨髓瘤患者骨髓移植前的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faa21e9006ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720902, encodeId=9f4a1e2090221, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性, objectType=article, longId=166325, objectId=1f1916632534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f1916632534, replyNumber=0, likeNumber=116, createdTime=2020-04-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f1916632534, moduleTitle=Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f1916632534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720897, encodeId=dd471e208979e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, objectType=article, longId=164438, objectId=87fe1644385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fe1644385f, replyNumber=0, likeNumber=52, createdTime=2020-02-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fe1644385f, moduleTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fe1644385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720887, encodeId=d8731e20887a3, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Gastroenterology：布地奈德与美沙拉嗪或安慰剂作为淋巴细胞性结肠炎的诱导治疗的疗效和安全性分析, objectType=article, longId=155495, objectId=0df4155495c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df4155495c9, replyNumber=0, likeNumber=155, createdTime=2019-04-03, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df4155495c9, moduleTitle=Gastroenterology：布地奈德与美沙拉嗪或安慰剂作为淋巴细胞性结肠炎的诱导治疗的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df4155495c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1720890, encodeId=eb7e1e2089014, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Gastroenterology：含有或不含利巴韦林的sofosbuvir-velpatasvir在HCV感染失代偿期肝硬化患者中的疗效和安全性分析, objectType=article, longId=157446, objectId=175b15e44699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=175b15e44699, replyNumber=0, likeNumber=55, createdTime=2019-11-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=175b15e44699, moduleTitle=J Gastroenterology：含有或不含利巴韦林的sofosbuvir-velpatasvir在HCV感染失代偿期肝硬化患者中的疗效和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=175b15e44699)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Int J Gynaecol Obstet：一项剂量范围研究，以确定每日1,2和4毫克地诺孕素对子宫内膜异位症的疗效和安全性

2019-07-09

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：Daratumumab单药疗法用于淀粉样变患者的疗效和安全性

2020-04-14

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：CD19 CAT-T细胞联合依鲁替尼治疗R/R CLL的疗效和安全性

2020-10-19

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性

2021-01-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性

2020-08-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

NEJM：Ubrogepant治疗偏头痛的疗效和安全性

2020-01-31

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

“三代同堂”谁领风骚？EGFR-TKI一线疗效和安全性大比拼

2019-11-06

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

J Rheumatol：TNF抑制剂在反应性关节炎中的疗效和安全性

2020-08-25

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet Oncol：Trebananib联合紫杉醇和卡铂作为一线疗法用于晚期卵巢癌患者的疗效和安全性

2019-12-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Am J Otolaryngol：舌下尘螨滴液在单敏或者多敏过敏性鼻炎患者中的疗效和安全性评估

2020-04-26

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：卡博替尼用于高度恶性的尤文肉瘤和骨肉瘤的疗效和安全性

2020-05-08

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

信达生物的TNF单抗仿制药IBI303治疗强直性脊柱炎，与修美乐疗效和安全性相当

2020-07-07

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Arthritis Rheumatol：卡那奴单抗对5岁以下cryopyrin蛋白相关周期性综合征患者具有长期疗效和安全性

2019-11-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：IFN-K治疗系统性红斑狼疮的疗效和安全性

2020-06-08

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：NI-0101对甲氨蝶呤反应不足类风湿性关节炎患者的疗效和安全性

2020-10-20

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：硼替佐米、来那度胺和地塞米松诱导方案用于多发性骨髓瘤患者骨髓移植前的疗效和安全性

2020-08-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Blood：利妥昔单抗联合来那度胺作为一线疗法用于滤泡性淋巴瘤患者的疗效和安全性

2020-04-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估

2020-02-19

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Gastroenterology：布地奈德与美沙拉嗪或安慰剂作为淋巴细胞性结肠炎的诱导治疗的疗效和安全性分析

2019-04-03

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Gastroenterology：含有或不含利巴韦林的sofosbuvir-velpatasvir在HCV感染失代偿期肝硬化患者中的疗效和安全性分析

2019-11-28

科室
- - 订阅+
  - 更多科室
工具
服务